These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34530305)

  • 21. Potential role of brivaracetam in pediatric epilepsy.
    Verrotti A; Grasso EA; Cacciatore M; Matricardi S; Striano P
    Acta Neurol Scand; 2021 Jan; 143(1):19-26. PubMed ID: 32966640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial.
    Kwan P; Trinka E; Van Paesschen W; Rektor I; Johnson ME; Lu S
    Epilepsia; 2014 Jan; 55(1):38-46. PubMed ID: 24116853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy, tolerability and pharmacokinetic variability of brivaracetam in adults with difficult-to-treat epilepsy.
    Svendsen T; Brodtkorb E; Linge HL; Burns ML; Johannessen SI; Nakken KO; Lossius MI; Landmark CJ
    Epilepsy Res; 2022 Jul; 183():106946. PubMed ID: 35609355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial.
    Biton V; Berkovic SF; Abou-Khalil B; Sperling MR; Johnson ME; Lu S
    Epilepsia; 2014 Jan; 55(1):57-66. PubMed ID: 24446953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term safety and efficacy of brivaracetam in adults with focal seizures: Results from an open-label, multinational, follow-up trial.
    Arnold S; Laloyaux C; Schulz AL; Elmoufti S; Yates S; Fakhoury T
    Epilepsy Res; 2020 Oct; 166():106404. PubMed ID: 32731118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapidity of CNS Effect on Photoparoxysmal Response for Brivaracetam vs. Levetiracetam: A Randomized, Double-blind, Crossover Trial in Photosensitive Epilepsy Patients.
    Reed RC; Rosenfeld WE; Lippmann SM; Eijkemans RMJC; Kasteleijn-Nolst Trenité DGA
    CNS Drugs; 2020 Oct; 34(10):1075-1086. PubMed ID: 32949370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: Pooled results from three Phase III studies.
    Moseley BD; Sperling MR; Asadi-Pooya AA; Diaz A; Elmouft S; Schiemann J; Whitesides J
    Epilepsy Res; 2016 Nov; 127():179-185. PubMed ID: 27608437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brivaracetam efficacy and safety in focal epilepsy.
    Makke Y; Abou-Khalil B
    Expert Rev Neurother; 2019 Oct; 19(10):955-964. PubMed ID: 31195850
    [No Abstract]   [Full Text] [Related]  

  • 29. Brivaracetam add-on treatment in pediatric patients with severe drug-resistant epilepsy: Italian real-world evidence.
    Russo A; Pruccoli J; Cesaroni CA; Belotti LMB; Zenesini C; Bonanni P; Boni A; Cesaroni E; Coppola G; Cordelli DM; Danieli A; Mancardi MM; Marchese F; Matricardi S; Messana T; Nocera GM; Operto FF; Pellino G; Reina F; Vanadia F; Verrotti A; Striano P
    Seizure; 2022 Nov; 102():120-124. PubMed ID: 36223675
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.
    Klitgaard H; Matagne A; Nicolas JM; Gillard M; Lamberty Y; De Ryck M; Kaminski RM; Leclercq K; Niespodziany I; Wolff C; Wood M; Hannestad J; Kervyn S; Kenda B
    Epilepsia; 2016 Apr; 57(4):538-48. PubMed ID: 26920914
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures.
    Mumoli L; Palleria C; Gasparini S; Citraro R; Labate A; Ferlazzo E; Gambardella A; De Sarro G; Russo E
    Drug Des Devel Ther; 2015; 9():5719-25. PubMed ID: 26543353
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and tolerability of adjunctive brivaracetam in epilepsy: In-depth pooled analysis.
    Brandt C; Klein P; Badalamenti V; Gasalla T; Whitesides J
    Epilepsy Behav; 2020 Feb; 103(Pt A):106864. PubMed ID: 31937513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness and tolerability of adjunctive brivaracetam in patients with focal seizures: Second interim analysis of 6-month data from a prospective observational study in Europe.
    Steinhoff BJ; Christensen J; Doherty CP; Majoie M; De Backer M; Hellot S; Leunikava I; Leach JP
    Epilepsy Res; 2020 Sep; 165():106329. PubMed ID: 32623096
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term efficacy and tolerability of adjunctive brivaracetam in adults with focal to bilateral tonic-clonic (secondary generalized) seizures: Post hoc pooled analysis.
    Moseley BD; Dimova S; Elmoufti S; Laloyaux C; Asadi-Pooya AA
    Epilepsy Res; 2021 Oct; 176():106694. PubMed ID: 34218211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical experience with brivaracetam in a series of 46 children.
    Visa-Reñé N; Raspall-Chaure M; Paredes-Carmona F; Coromina JS; Macaya-Ruiz A
    Epilepsy Behav; 2020 Jun; 107():107067. PubMed ID: 32302941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam.
    Yates SL; Fakhoury T; Liang W; Eckhardt K; Borghs S; D'Souza J
    Epilepsy Behav; 2015 Nov; 52(Pt A):165-8. PubMed ID: 26432008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus.
    Strzelczyk A; Kay L; Bauer S; Immisch I; Klein KM; Knake S; Kowski A; Kunz R; Kurlemann G; Langenbruch L; Möddel G; Müller-Schlüter K; Reif PS; Schubert-Bast S; Steinhoff BJ; Steinig I; Willems LM; von Podewils F; Rosenow F
    Epilepsia; 2018 Aug; 59(8):1549-1556. PubMed ID: 29943451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Brivaracetam in the treatment of patients with epilepsy].
    Karlov VA; Vlasov PN; Zhidkova IA; Kissin MY; Lebedeva AV; Lipatova LV; Mkrtchyan VR; Mukhin KY; Rudakova IG
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(9. Vyp. 2):55-62. PubMed ID: 29213040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of lifetime antiepileptic drug treatment history on efficacy and tolerability of adjunctive brivaracetam in adults with focal seizures: Post-hoc analysis of a randomized, placebo-controlled trial.
    Klein P; McLachlan R; Foris K; Nondonfaz X; Elmoufti S; Dimova S; Brandt C
    Epilepsy Res; 2020 Nov; 167():106369. PubMed ID: 32717713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the effectiveness and tolerability of perampanel and brivaracetam: a real-world, observational, retrospective study.
    Liguori C; Manfredi N; Renna R; Izzi F; Pagliuca M; Pagliuca F; Mercuri NB; Fabio P
    Epileptic Disord; 2020 Jun; 22(3):309-316. PubMed ID: 32540833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.